Should you buy Pfizer stock now?
Yes, the technical signal for Pfizer is currently BUY. Pfizer trades at $25.98 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.259 with rising momentum (signal: 0.115); RSI is at 66.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $28.75 points to 10.7% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Pfizer stock?
The average analyst price target for Pfizer is $28.75. The current price is $25.98, which gives an upside of 10.7%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $25.88 and $31.63.
Is Pfizer a dividend stock?
No, Pfizer does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Pfizer stock?
Pfizer is rated as a stock with low risk. the annual standard deviation is 23.2%, which classifies the stock as low risk.
Is Pfizer overvalued?
No, Pfizer is considered undervalued based on the analyst price target (10.7% upside). Pfizer has the following valuation ratios: a P/E ratio of 19.1 (moderately valued), a P/S ratio of 2.3, a P/B ratio of 1.6. The analyst price target suggests that the stock is undervalued by 10.7%.
Is Pfizer overbought?
No, Pfizer is not overbought. RSI is at 66.8 (neutral zone). The technical indicators show: RSI is at 66.8 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 5.4% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Pfizer earnings report?
The date of the next earnings report for Pfizer has not been published yet. Check the company's investor calendar for updates.
Is Pfizer shorted?
Yes, Pfizer is shorted with 2.9% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Pfizer stock?
Yes, insiders are net buyers of Pfizer – they are buying more shares than they are selling. Over the last 3 months, insiders have made 2 purchases and 1 sales. On a net basis, 1,907,790 $ worth of shares were bought. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 24,186,574 $ sold. Active buyers include Buckley Mortimer J, BLAYLOCK RONALD E. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Pfizer a good stock?
Based on our total score, Pfizer is rated as a good stock with a total score of 72 out of 100. The stock scores above average on value, quality and momentum – it is among the top 28% in our database. The score is made up of Value: 72/100, Quality: 78/100, Momentum: 67/100. In addition: analysts see 10.7% upside to the price target; technical signal: Buy. Whether Pfizer is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Pfizer stock?
The outlook for Pfizer based on current data: the average analyst price target is $28.75 (+10.7%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 19.1 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Pfizer stock rising?
Pfizer is rising right now. The technical indicators show: the price is 5.4% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Pfizer go?
The average analyst price target for Pfizer is $28.75, which corresponds to a potential gain of 10.7% from the current price of $25.98. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Pfizer fall?
We lack enough history to give a specific floor for Pfizer. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Pfizer do?
Pfizer Inc. driver en stor forretning, hvor de opdager, udvikler og sælger biofarmaceutiske produkter over hele verden. De tjener primært penge på medicin og vacciner til mange forskellige sygdomsområder.
For eksempel laver Pfizer behandlinger for hjerte-kar-sygdomme som Eliq... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Pfizer as an investment.
Did Pfizer raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Pfizer. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Pfizer making money or losing money?
Yes, Pfizer is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 11.8% — which is solid. The operating margin (profit before interest and taxes) is 31.6%. At a P/E ratio of 19.1, you currently pay 19.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Pfizer go bankrupt?
The bankruptcy risk of Pfizer is rated as low. Altman Z2 (a model for assessing financial distress) is 3.11 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 142% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Pfizer have a lot of debt?
Pfizer has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 142%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Pfizer service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is 0.0x, and net debt equals 2.4 years of earnings (EBITDA).
